Figure 1: Overexpression of TRIB2 confers in vitro resistance to PI3K inhibitors. | Nature Communications

Figure 1: Overexpression of TRIB2 confers in vitro resistance to PI3K inhibitors.

From: RETRACTED ARTICLE: TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT

Figure 1

(a) Matched isogenic TRIB2 cell line FACS analysis following exposure to BEZ235 (n=6), sc.shRNA indicates scramble shRNA while TRIB2 shRNA indicates stable shRNA knockdown for TRIB2 in each cell lines. P values are indicated for each comparison by two-way analysis of variance (ANOVA) and data represent the mean±s.d. (b) (left) Higher pro-caspase3 and reduced cleavage of caspase3 in TRIB2 overexpressing cells after treatment with BEZ235, (50 μg total protein loaded per lane and separated by 10% SDS–PAGE). (right) Densitometry for cleaved caspase3 and TRIB2 under each condition. Data normalized to actin and analysed in ImageJ. Data indicates relative mean intensity±s.e.m and analysed by two-way ANOVA. (c) Schematic showing the target specificity for each compound, the inhibitory concentration 50% (IC50) and commercial name. (d) FACS analysis of TRIB2 isogenic cell lines 72 h post exposure to various pre-clinical PI3K inhibitors (n=6). (e) Isogenic TRIB2 cell line FACS analysis 72 h post-AKT, mTOR1/2 or mTOR1 inhibition (n=6). P values are indicated for each comparison by two-way analysis of variance (ANOVA) and data represent the mean±s.d.

Back to article page